740 related articles for article (PubMed ID: 23197041)
1. The potential of biologics for the treatment of asthma.
Pelaia G; Vatrella A; Maselli R
Nat Rev Drug Discov; 2012 Dec; 11(12):958-72. PubMed ID: 23197041
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
[TBL] [Abstract][Full Text] [Related]
3. Promises and challenges of biologics for severe asthma.
Tan R; Liew MF; Lim HF; Leung BP; Wong WSF
Biochem Pharmacol; 2020 Sep; 179():114012. PubMed ID: 32389637
[TBL] [Abstract][Full Text] [Related]
4. Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents.
Huffaker MF; Phipatanakul W
Immunol Allergy Clin North Am; 2015 Feb; 35(1):129-44. PubMed ID: 25459581
[TBL] [Abstract][Full Text] [Related]
5. Anti-IgE therapy with omalizumab for severe asthma: current concepts and potential developments.
Pelaia G; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Maselli R
Curr Drug Targets; 2015; 16(2):171-8. PubMed ID: 25523898
[TBL] [Abstract][Full Text] [Related]
6. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody.
Silkoff PE; Romero FA; Gupta N; Townley RG; Milgrom H
Pediatrics; 2004 Apr; 113(4):e308-12. PubMed ID: 15060258
[TBL] [Abstract][Full Text] [Related]
7. Severe Eosinophilic Allergic Asthma Responsive to Mepolizumab After Failure of 2 Consecutive Biologics.
Sánchez-Jareño M; Barranco P; Romero D; Domínguez-Ortega J; Quirce S
J Investig Allergol Clin Immunol; 2019 Feb; 29(1):79-81. PubMed ID: 30785114
[No Abstract] [Full Text] [Related]
8. Molecular Targets for Biological Therapies of Severe Asthma.
Pelaia C; Crimi C; Vatrella A; Tinello C; Terracciano R; Pelaia G
Front Immunol; 2020; 11():603312. PubMed ID: 33329598
[TBL] [Abstract][Full Text] [Related]
9. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma.
Hoshino M; Ohtawa J
Respiration; 2012; 83(6):520-8. PubMed ID: 22236804
[TBL] [Abstract][Full Text] [Related]
10. An update on biologic-based therapy in asthma.
Walsh GM
Immunotherapy; 2013 Nov; 5(11):1255-64. PubMed ID: 24188679
[TBL] [Abstract][Full Text] [Related]
11. Update on anticytokine treatment for asthma.
Gallelli L; Busceti MT; Vatrella A; Maselli R; Pelaia G
Biomed Res Int; 2013; 2013():104315. PubMed ID: 23853765
[TBL] [Abstract][Full Text] [Related]
12. Role of Biologics in Asthma.
McGregor MC; Krings JG; Nair P; Castro M
Am J Respir Crit Care Med; 2019 Feb; 199(4):433-445. PubMed ID: 30525902
[TBL] [Abstract][Full Text] [Related]
13. [Asthma therapy in transition. "For the physician it becomes ever more complicated" (interview by Dr. Elke Oberhofer)].
Gillissen A; Oberhofer E
MMW Fortschr Med; 2014 Jun; 156(11):31. PubMed ID: 25022087
[No Abstract] [Full Text] [Related]
14. Against all odds: anti-IgE for intrinsic asthma?
Lommatzsch M; Korn S; Buhl R; Virchow JC
Thorax; 2014 Jan; 69(1):94-6. PubMed ID: 23709757
[TBL] [Abstract][Full Text] [Related]
15. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
16. Spotlight on omalizumab in allergic asthma.
Bang LM; Plosker GL
BioDrugs; 2004; 18(6):415-8. PubMed ID: 15571425
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab for asthma in adults and children.
Normansell R; Walker S; Milan SJ; Walters EH; Nair P
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD003559. PubMed ID: 24414989
[TBL] [Abstract][Full Text] [Related]
18. Biologic agents for severe asthma patients: clinical perspectives and implications.
Caruso M; Morjaria J; Emma R; Amaradio MD; Polosa R
Intern Emerg Med; 2018 Mar; 13(2):155-176. PubMed ID: 29238905
[TBL] [Abstract][Full Text] [Related]
19. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.
Hanania NA; Alpan O; Hamilos DL; Condemi JJ; Reyes-Rivera I; Zhu J; Rosen KE; Eisner MD; Wong DA; Busse W
Ann Intern Med; 2011 May; 154(9):573-82. PubMed ID: 21536936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
